CABA logo

Cabaletta Bio Inc. (CABA)

$1.02

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CABA

Market cap

$220034800

EPS

-1.23

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

3.558618

Price on CABA

Previous close

$1.11

Today's open

$1.09

Day's range

$0.98 - $1.16

52 week range

$0.98 - $4.23

Profile about CABA

CEO

Steven Nichtberger

Employees

156

Headquarters

Philadelphia, PA

Exchange

Nasdaq Global Select

Shares outstanding

215720392

Issue type

Common Stock

CABA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CABA

Cabaletta Bio: Revisiting A Wrong Call

Cabaletta Bio remains a Buy: its $276 million valuation sits below $299 million in cash, assigning little value to rese-cel. Rese-cel shows encouraging autoimmune responses and tolerability, but CABA's dermatomyositis readout has slipped to late 2027, with a 2028 BLA planned. Cash should fund CABA into Q1 2028, placing the submission near the end of its runway and making further dilution likely.

news source

Seeking Alpha • Nov 16, 2026

news preview

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases

100% (6 of 6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year, with most patients also free of steroids

news source

GlobeNewsWire • Nov 8, 2026

news preview

Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data

news source

GlobeNewsWire • Nov 5, 2026

news preview

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 4, 2026

news preview

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio is rated Buy, trading 40% below its $2.41 pipeline value despite a single-asset risk profile. CABA's lead CAR T asset, rese-cel, targets severe autoimmune diseases with pivotal Phase 1/2 data expected mid-2027 and BLA submission planned for late 2027. A recent 10-year manufacturing deal with Cellares lowers future COGS, supporting margin expansion if rese-cel is approved.

news source

Seeking Alpha • Oct 13, 2026

news preview

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 14, 2026

news preview

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis ® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel

news source

GlobeNewsWire • Aug 13, 2026

news preview

Cabaletta Bio: The Market Sold The EULAR News, I'm Buying

Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.

news source

Seeking Alpha • Jun 26, 2026

news preview

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Jun 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Cabaletta Bio Inc.

Open an M1 investment account to buy and sell Cabaletta Bio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CABA on M1